Share ownership Biogen Inc.

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
196.52 ^USD	+0.52%		-2.32%	+11.67%

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…

Share class: Biogen Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	170,174,937	145,495,299 ( 85.5 %)	23,800,000 ( 13.99 %)	85.5 %

Major shareholders: Biogen Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 11.89 %	17,447,092	11.89 %	3 139 M $
PRIMECAP Management Co. 10.06 %	14,757,997	10.06 %	2 655 M $
BlackRock Advisors LLC 7.288 %	10,691,279	7.288 %	1 923 M $
STATE STREET CORPORATION 4.88 %	7,159,020	4.88 %	1 288 M $
Wellington Trust Co., NA 2.895 %	4,246,504	2.895 %	764 M $
Geode Capital Management LLC 2.863 %	4,199,399	2.863 %	755 M $
Point72 Asset Management LP 2.64 %	3,872,901	2.64 %	697 M $
BlackRock Life Ltd. 2.592 %	3,802,367	2.592 %	684 M $
Norges Bank (13F) 1.799 %	2,638,834	1.799 %	475 M $
Invesco Advisers, Inc. 1.648 %	2,418,127	1.648 %	435 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	77.76%
Other	9.56%
State Street Corp.	4.88%
Schweizerische Nationalbank	0.27%
Sumitomo Mitsui Trust Group, Inc.	0.25%
Individuals	0.21%
Swedbank AB	0.16%
Governments	0.16%
Banco Bilbao Vizcaya Argentaria SA	0.09%
SEI Investments Co.	0.08%
Manulife Financial Corp.	0.07%
Danske Bank A/S	0.03%
Meitav Investment House Ltd.	0.02%
Baader Bank AG	0.02%
Skandinaviska Enskilda Banken AB	0.02%
The Bank of Nova Scotia	0.02%
The Allstate Corp.	0.01%
Fifth Third Bancorp	0.01%
Unknown	6.37%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	72.02%
United Kingdom	9.13%
Canada	2.29%
Norway	2.05%
Switzerland	1.38%
Australia	0.95%
France	0.9%
Japan	0.85%
Sweden	0.59%
Netherlands	0.55%
Hong Kong	0.43%
Germany	0.32%
Luxembourg	0.3%
Spain	0.28%
Ireland	0.26%
South Korea	0.23%
Individuals	0.21%
Italy	0.15%
Israel	0.09%
China	0.09%
Finland	0.09%
Denmark	0.08%
Austria	0.06%
Czech Republic	0.06%
Singapore	0.05%
Belgium	0.04%
Bermuda	0.04%
New Zealand	0.03%
Slovenia	0.03%
Taiwan	0.02%
Cayman Islands	0.01%
Mexico	0.01%
South Africa	0.01%
India	0.01%
Liechtenstein	0.01%
Brazil	0.01%

Based on 1000 largest holdings

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.

Employees

7,500

Sector

Pharmaceuticals

Calendar

05-05 - Q1 2026 Earnings Release (Projected)

More about the company